|
1
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ayyub MI, Al-Radi AO, Khazeindar AM, Nagi AH and Maniyar IA: Clinicopathological trends in colorectal cancer in a tertiary care hospital. Saudi Med J. 23:160–163. 2002.PubMed/NCBI
|
|
4
|
Mosli MH and Al-Ahwal MS: Colorectal cancer in the kingdom of Saudi Arabia: Need for screening. Asian Pac J Cancer Prev. 13:3809–3813. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tiash S and Chowdhury EH: Growth factor receptors: Promising drug targets in cancer. J Cancer Metastasis Treat. 1:190–200. 2015.
|
|
6
|
Witsch E, Sela M and Yarden Y: Roles for growth factors in cancer progression. Physiology (Bethesda). 25:85–101. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kantola T, Klintrup K, Vayrynen JP, Vornanen J, Bloigu R, Karhu T, Herzig KH, Napankangas J, Mäkelä J, Karttunen TJ, et al: Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. Br J Cancer. 107:1729–1736. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Krzystek-Korpacka M, Diakowska D, Kapturkiewicz B, Bębenek M and Gamian A: Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillance. Cancer Lett. 337:107–114. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tang Y, Liao C, Xu X, Song H, Shi S and Yang S: Th1/Th2 cytokine profiles in G+/G- bacteremia in pediatric hematology/oncology patients. Pediatr Blood Cancer. 58:50–54. 2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Venere M, Lathia JD and Rich JN: Growth factor receptors define cancer hierarchies. Cancer Cell. 23:135–137. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Cohen RB: Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer. 2:246–251. 2003.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Pabla B, Bissonnette M and Konda VJ: Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention. World J Clin Oncol. 6:133–141. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, Rossi C, Baldelli AM, Graziano F, Saba V, et al: Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res. 6:2803–2807. 2000.PubMed/NCBI
|
|
14
|
Rapisarda A and Melillo G: Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res. 114:237–267. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gohji K, Nomi M, Niitani Y, Kitazawa S, Fujii A, Katsuoka Y and Nakajima M: Independent prognostic value of serum hepatocyte growth factor in bladder cancer. J Clin Oncol. 18:2963–2971. 2000.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Naughton M, Picus J, Zhu X, Catalona WJ, Vollmer RT and Humphrey PA: Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. J Urol. 165:1325–1328. 2001.PubMed/NCBI
|
|
17
|
Toiyama Y, Miki C, Inoue Y, Okugawa Y, Tanaka K and Kusunoki M: Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. Int J Cancer. 125:1657–1662. 2009.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hanzawa M, Shindoh M, Higashino F, Yasuda M, Inoue N, Hida K, Ono M, Kohgo T, Nakamura M, Notani K, et al: Hepatocyte growth factor upregulates E1AF that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes. Carcinogenesis. 21:1079–1085. 2000.PubMed/NCBI
|
|
19
|
Sobin LH and Compton CC: TNM seventh edition: What's new, what's changed: Communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer. 116:5336–5339. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Al Obeed OA, Alkhayal KA, Al Sheikh A, Zubaidi AM, Vaali-Mohammed MA, Boushey R, McKerrow JH and Abdulla MH: Increased expression of tumour necrosis factor-alpha is associated with advanced colorectal cancer stages. World J Gastroenterol. 20:18390–18396. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Al Obeed OA, Alkhayal KA, Al Sheikh A, Zubaidi AM, Vaali-Mohammed MA, Boushey R, Mckerrow JH and Abdulla MH: Increased expression of tumor necrosis factor-α is associated with advanced colorectal cancer stages. World J Gastroenterol. 20:18390–18396. 2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar
|
|
24
|
De Divitiis C, Nasti G, Montano M, Fisichella R, Iaffaioli RV and Berretta M: Prognostic and predictive response factors in colorectal cancer patients: Between hope and reality. World J Gastroenterol. 20:15049–15059. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Inanc M, Er O, Karaca H, Berk V, Ozkan M, Saraymen R and Elmali F: Prognostic value of tumour growth factor levels during chemotherapy in patients with metastatic colorectal cancer. Med Oncol. 29:3119–3124. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yoon SS, Kim SH, Gonen M, Heffernan NM, Detwiller KY, Jarnagin WR, D'Angelica M, Blumgart LH, Tanabe KK and Dematteo RP: Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol. 13:353–362. 2006.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjänen S, Syrjänen K, Collan Y and Pyrhönen S: VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res. 28:3865–3870. 2008.PubMed/NCBI
|
|
28
|
Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, Lin Z and Zhu B: IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun. 407:348–354. 2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Martins SF, Garcia EA, Luz MA, Pardal F, Rodrigues M and Filho AL: Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. Cancer Genomics Proteomics. 10:55–67. 2013.PubMed/NCBI
|
|
30
|
Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, Breau JL and Perret GY: Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 94:1823–1832. 2006.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kwon KA, Kim SH, Oh SY, Lee S, Han JY, Kim KH, Goh RY, Choi HJ, Park KJ, Roh MS, et al: Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer. 10(203)2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Eldesoky A, Shouma A, Mosaad Y and Elhawary A: Clinical relevance of serum vascular endothelial growth factor and interleukin-6 in patients with colorectal cancer. Saudi J Gastroenterol. 17:170–173. 2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Lee JC, Chow NH, Wang ST and Huang SM: Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer. 36:748–753. 2000.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Coşkun Ö, Öztopuz Ö and Özkan ÖF: Determination of IL-6, TNF-α and VEGF levels in the serums of patients with colorectal cancer. Cell Mol Biol (Noisy-le-grand). 63:97–101. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
George ML, Tutton MG, Janssen F, Arnaout A, Abulafi AM, Eccles SA and Swift RI: VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia. 3:420–427. 2001.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Balcan E, Demirkiran F, Aydin Y, Sanioglu C, Bese T, Arvas M, Akçay T and Cift T: Serum levels of epidermal growth factor, transforming growth factor, and c-erbB2 in ovarian cancer. Int J Gynecol Cancer. 22:1138–1142. 2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, Attar A, Benichou J, Martin A, Morere JF, et al: Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 16:102–108. 2005.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Cheirsilpa A, Ruangvejvorachai P, Karalak A, Sangprakarn S, Pummai S and Sangrajrang S: Determination of epidermal growth factor receptor (EGFR) in patients with colorectal cancer. Cancer Ther. 5:137–142. 2007.
|
|
39
|
Arteaga CL: The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol. 19 (Suppl 18):S32–S40. 2001.PubMed/NCBI
|
|
40
|
Yarden Y: The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer. 37 (Suppl 4):S3–S8. 2001.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Goldstein NS and Armin M: Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint committee on cancer stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer. 92:1331–1346. 2001.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Lemos-Gonzalez Y, Rodriguez-Berrocal FJ, Cordero OJ, Gómez C and Paez de la Cadena M: Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma. Br J Cancer. 96:1569–1578. 2007.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Kermorgant S, Zicha D and Parker PJ: PKC controls HGF-dependent c-Met traffic, signalling and cell migration. EMBO J. 23:3721–3734. 2004.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Li F and Zhu YT: HGF-activated colonic fibroblasts mediates carcinogenesis of colonic epithelial cancer cells via PKC-cMET-ERK1/2-COX-2 signaling. Cell Signal. 27:860–866. 2015.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Yao JF, Li XJ, Yan LK, He S, Zheng JB, Wang XR, Zhou PH, Zhang L, Wei GB and Sun XJ: Role of HGF/c-Met in the treatment of colorectal cancer with liver metastasis. J Biochem Mol Toxicol. 33(e22316)2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Easton DF and Eeles RA: Genome-wide association studies in cancer. Hum Mol Genet. 17:R109–R115. 2008.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Vogel C and Marcotte EM: Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 13:227–232. 2012.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Plaks V, Kong N and Werb Z: The cancer stem cell niche: How essential is the niche in regulating stemness of tumour cells? Cell Stem Cell. 16:225–238. 2015.PubMed/NCBI View Article : Google Scholar
|
